SEC filing · 8-K

Aardvark Therapeutics, Inc.: Executive or director change

Aardvark Therapeutics appointed Dr. David Zhang as an independent Class II director.

Filed October 8, 2026

Positive for the company

What happened

The board of directors appointed David Zhang as a Class II director effective October 7, 2026.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov Press release (EX-99.1) All documents of this filing

Back to Aardvark Therapeutics, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.